lercanidipine (Zanidip)

Indications

• treatment of hypertension

Contraindications

• see calcium channel blocker

Pharmacokinetics

• metabolized by CYP3A4

Drug interactions

• lercanidipine increases plasma levels of cyclosporin & digoxin

• drug interaction(s) of calcium channel blockers with ARBs
• drug interaction(s) of calcium channel blockers with ACE inhibitors
• drug interaction(s) of calcium channel blockers with diuretics
• drug interaction(s) of calcium channel blockers with erythromycin
• drug interaction(s) of calcium channel blockers with clarithromycin
• drug interaction(s) of renin-angiotensin-aldosterone inhibitors with trimethoprim-sulfamethoxazole
• drug interaction(s) of beta-adrenergic receptor antagonists with calcium channel blockers
• drug interaction(s) of NSAIDs & antihypertensives

Mechanism of action

• like other dihydropyridine calcium channel blockers, lercanidipine blocks L-type calcium channels in vascular smooth muscle cells, relaxing them & lowering blood pressure

More general terms

• calcium channel blocker (CCB)
• dihydropyridine

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=65866
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=157917